Diffuse alveolar hemorrhage following alemtuzumab

Chest

Volumn 133, Issue 6, 2008, Pages 1476-1478

  Sachdeva, Ashutosh ^a   Matuschak, George M ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alemtuzumab; ARDS; Diffuse alveolar hemorrhage

Indexed keywords

ALEMTUZUMAB; ALLOANTIBODY; AUTOANTIBODY; CALCIUM ACETATE; COLLAGEN TYPE 4; GLOMERULUS BASEMENT MEMBRANE ANTIBODY; IMMUNOSUPPRESSIVE AGENT; MULTIVITAMIN; RAPAMYCIN; STEROID; TACROLIMUS;

ACUTE KIDNEY FAILURE; ACUTE KIDNEY TUBULE NECROSIS; ACUTE RESPIRATORY FAILURE; ADULT; ALPORT SYNDROME; ANEMIA; ARTICLE; ARTIFICIAL VENTILATION; BRONCHOSCOPY; CADAVER KIDNEY; CASE REPORT; CHRONIC ALLOGRAFT NEPHROPATHY; COMPUTER ASSISTED TOMOGRAPHY; DIFFUSE ALVEOLAR HEMORRHAGE; DISEASE COURSE; DISEASE PREDISPOSITION; DYSPNEA; HEMODIALYSIS; HEMOPTYSIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT; KIDNEY BIOPSY; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LUNG ALVEOLUS; LUNG HEMORRHAGE; LUNG LAVAGE; LUNG TOXICITY; MALE; PLASMAPHERESIS; PRIORITY JOURNAL; SINGLE DRUG DOSE; STEROID THERAPY; THORAX RADIOGRAPHY; THROMBOCYTOPENIA; TREATMENT OUTCOME; UREMIA; X CHROMOSOME LINKED DISORDER;

EID: 45949093191     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.07-2354     Document Type: Article

References (11)

1. Morris PJ, Russell NK. Alemtuzumab (Campath-1H): a systematic review in organ transplantation. Transplantation 2006; 81:1361-1367
2. Magliocca JF, Knechtle SJ. The evolving role of alemtuzumab (Campath-1H) for immunosuppressive therapy in organ transplantation. Transpl Int 2006; 19:705-714
3. Charytan D, Torre A, Khurana M, et al. Allograft rejection and glomerular basement membrane antibodies in Alport's syndrome. J Nephrol 2004; 17:431-435
4. Afessa B, Tefferi A, Litzow MR, et al. Outcomes of diffuse alveolar hemorrhage in hematopoeitic stem cell transplant recipients. Am J Respir Crit Care Med 2002; 166:1364-1368
5. Mal H, Veyradier A, Fournier M, et al. Thrombotic microangiopathy with acquired deficiency of ADAMTS 13 activity in lung transplant recipients. Transplantation 2006; 81:1628-1632
6. US Food and Drug Administration. FDA alert for healthcare professionals: alemtuzumab. Available at: http://www.fda.gov/cder/drug/infopage/alemtuzumab/ default.htm. Accessed January 25, 2007
7. Kalra S, Bell MR, Rihal CS. Alveolar hemorrhage as a complication of treatment with abciximab. Chest 2001; 120:126-131
8. Lin TS, Penza SL, Copelan EA et al. Diffuse alveolar hemorrhage following gemtuzumab ozogamicin. Bone Marrow Transplant 2005; 35:823-824
9. Schwarz MI, Fontenot AP. Drug-induced diffuse alveolar hemorrhage syndromes and vasculitis. Clin Chest Med 2004; 25:133-140
10. Kang JS, Kashtan CE, et al. The alloantigenic sites of α3α4α5(IV) collagen: pathogenic X-linked Alport alloantibodies target two accessible conformational epitopes in the α5NC1 domain. J Biol Chem 2007; 282:10670-10677
11. Kalluri R, Shield CF, Todd P, et al. Isoform switching of type IV collagen is developmentally arrested in X-linked Alport syndrome leading to increased susceptibility of renal basement membrane to endoproteolysis. J Clin Invest 1997; 99:2470-2478